Merck (MRK) Equity Average (2009 - 2026)

Merck (MRK) has 18 years of Equity Average data on file, last reported at $49.3 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $49.3 billion, up 3.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.3 billion (up 3.98% YoY), and the FY2025 annual result was $49.5 billion, up 17.89% from the prior year.
• Equity Average fell to $49.3 billion in Q1 2026 per MRK's latest filing, from $52.3 billion in the prior quarter.
• Over five years, Equity Average peaked at $52.3 billion in Q4 2025 and troughed at $39.0 billion in Q1 2024.
• A 5-year average of $44.6 billion and a median of $44.1 billion in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average jumped 51.04% in 2022, then fell 16.03% in 2024.
• A 5-year view of Equity Average shows it stood at $45.3 billion in 2022, then fell by 12.86% to $39.5 billion in 2023, then advanced by 15.2% to $45.5 billion in 2024, then advanced by 14.93% to $52.3 billion in 2025, then declined by 5.71% to $49.3 billion in 2026.
• Business Quant data shows MRK's Equity Average at $49.3 billion in Q1 2026, $52.3 billion in Q4 2025, and $50.5 billion in Q3 2025.